Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis

Upchurch, Katherine S.; Heller, Kim; Bress, Norman M.

doi:10.1016/s0190-9622(87)70212-6

Cited by 33 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some reports have discussed the effectiveness of MTXfor cutaneous vasculitis (12,13), and aggravation of systemic rheumatoid vasculitis after discontinuation of MTX (14). Other reports have described accelerated nodulosis and vasculitis during MTXtherapy forrheumatoid arthritis ( 1 5 , 1 6).…”

Section: Discussionmentioning

confidence: 99%

Recovery from Rheumatoid Cerebral Vasculitis by Low-Dose Methotrexate.

et al. 1994

View full text Add to dashboard Cite

Wereport the successful managementof cerebral vasculitis in a 46-year-old womanwith longstanding rheumatoid arthritis with low-dose methotrexate. She suddenly developed dysarthria and left hemiparesis. Magnetic resonance imaging disclosed ischemia of the right pons, and angiography demonstrated cerebral vasculitis of vertebro-basilar arteries. The vasculitis was refractory with high-dose steroid therapy, which had only transient clinical benefit, and evolution to the pontine infarction followed. Her clinical status showed marked improvement in association with recovery of the vascular abnormalities after the initiation of the methotrexate therapy. (Internal Medicine 33: 615-620, 1994)

show abstract

Section: Discussionmentioning

confidence: 99%

Recovery from Rheumatoid Cerebral Vasculitis by Low-Dose Methotrexate.

et al. 1994

View full text Add to dashboard Cite

show abstract

“…It is well-studied in RA, decreases erosive arthritis and systemic inflammation, and reports support its use in RA vasculitis [27, 28]. We start with a dose of 10 mg/wk and titrate up to a dose of 20 to 25 mg/wk based on efficacy and adverse events.…”

Section: Treatmentmentioning

confidence: 99%

Rheumatoid Vasculitis: Vanishing Menace or Target for New Treatments?

Bartels

Bridges

2010

Curr Rheumatol Rep

View full text Add to dashboard Cite

Rheumatoid vasculitis is a rare but serious complication of rheumatoid arthritis. Herein we examine the pathophysiology, epidemiology, clinical diagnosis, and treatment of rheumatoid vasculitis. Seropositivity, specific HLA variations, and tobacco use are among the genetic and environmental predictors of rheumatoid vasculitis. Fortunately, recent reports have noted declines in the prevalence of rheumatoid vasculitis. Nevertheless, proper recognition of systemic manifestations may assist in pathologically confirming the diagnosis, determining the extent of disease, and guiding treatment. Contemporary treatment reports are discussed in the context of the ongoing debate regarding whether new agents may trigger, treat, or even prevent rheumatoid vasculitis. Evolving genetic, histopathologic, and immunologic studies partnered with ongoing clinical experience with biologics offer promise to inform future prevention and treatment of rheumatoid vasculitis.

show abstract

“…It is widely used in the treatment of uncomplicated rheumatoid arthritis and there are several uncontrolled reports of its efficacy in cutaneous vasculitis associated with rheumatoid arthritis (Espinoza et al, 1986;Upchurch et al, 1987;Williams & Pembroke, 1989). Interestingly, its use in rheumatoid arthritis has been complicated by the abrupt development of nodulosis and other vasculitic manifestations (Fondevila-Carlos et al, 1989;Jeurissen et al, 1989;Navarro et al, 1986;Segal et al, 1988).…”

Section: Other Therapiesmentioning

confidence: 99%